VTRS vs AMRX

For growth investors, Amneal Pharmaceuticals, Inc.

(AMRX) is the stronger pick with 8. 0% revenue growth year-over-year, versus -3. 0% for Viatris Inc. (VTRS). Amneal Pharmaceuticals, Inc. (AMRX) offers the better valuation at 61. 9x trailing P/E (13. 7x forward), making it the more compelling value choice. Analysts rate Amneal Pharmaceuticals, Inc. (AMRX) a "Buy" — based on 16 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Viatris Inc.

is actually cheaper at 6. 5x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Amneal Pharmaceuticals, Inc.

(AMRX) delivered a total return of +135. 6%, compared to +31. 5% for Viatris Inc. (VTRS). Over 10 years, the gap is even starker: VTRS returned -53. 8% versus AMRX's -54. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Viatris Inc.

(VTRS) is the lower-risk stock at 0. 99β versus Amneal Pharmaceuticals, Inc. 's 1. 17β — meaning AMRX is approximately 18% more volatile than VTRS relative to the S&P 500. On balance sheet safety, Amneal Pharmaceuticals, Inc. (AMRX) carries a lower debt/equity ratio of 13% versus 98% for Viatris Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Amneal Pharmaceuticals, Inc.

(AMRX) is pulling ahead at 8. 0% versus -3. 0% for Viatris Inc. (VTRS). On earnings-per-share growth, the picture is similar: Amneal Pharmaceuticals, Inc. grew EPS 157. 9% year-over-year, compared to -466. 0% for Viatris Inc.. Over a 3-year CAGR, AMRX leads at 10. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Amneal Pharmaceuticals, Inc.

(AMRX) is the more profitable company, earning 2. 4% net margin versus -24. 6% for Viatris Inc. — meaning it keeps 2. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AMRX leads at -0. 2% versus -18. 6% for VTRS. At the gross margin level — before operating expenses — AMRX leads at 36. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Viatris Inc.

(VTRS) trades at 6. 5x forward P/E versus 13. 7x for Amneal Pharmaceuticals, Inc. — 7. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AMRX: 24. 8% to $17. 00.

In this comparison, VTRS (3.

0% yield) pays a dividend. AMRX does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Viatris Inc.

(VTRS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 99), 3. 0% yield). Both have compounded well over 10 years (VTRS: -53. 8%, AMRX: -54. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: VTRS is a mid-cap income-oriented stock; AMRX is a small-cap quality compounder stock. VTRS pays a dividend while AMRX does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.